Vimarsana
Biggest News Aggregation in the World

Page 26 - Outlayer Item News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Outlayer Item. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Outlayer Item Today - Breaking & Trending Today

Q&A: AKI, CKD prevalence in transgender patients - Vimarsana News

Q&A: AKI, CKD prevalence in transgender patients

AKI and chronic kidney disease prevalence is high among transgender patients, but this is rarely researched, according to a cross-sectional study published in the Clinical Journal of the American Society of Nephrology.Currently, there are limited data regarding kidney disease in transgender populations. The first study of its kind examined a cohort of 274 transgender patients receiving

Source: healio.com
ACR guidelines: 'Turn the pyramid upside down' for biologic DMARDs in JIA - Vimarsana News

ACR guidelines: 'Turn the pyramid upside down' for biologic DMARDs in JIA

The American College of Rheumatology has released two updated guideline papers for the treatment and management of juvenile idiopathic arthritis, according to a press release. “As rheumatologists, our patients and caregivers expect us to review the literature and weigh the evidence so that we can suggest the best treatments, while also considering their preferences,” Karen Onel, MD,

Source: healio.com
Outpatient antibiotics improve care for drug use-associated infective endocarditis - Vimarsana News

Outpatient antibiotics improve care for drug use-associated infective endocarditis

Outpatient antibiotics improved outcomes for patients with injection drug use-associated infective endocarditis compared with patients who received inpatient IV therapy, according to a study. Between 2003 and 2016, hospitalizations associated with infective endocarditis increased from 16 per 100,000 adults in to 22 per 100,000 adults, and 10% of the hospitalizations are now a result of injection

Source: healio.com
Three-drug regimen may reduce relapse risk after transplant for T-cell malignancies - Vimarsana News

Three-drug regimen may reduce relapse risk after transplant for T-cell malignancies

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.The three-drug combination also mitigated the poor outcomes of patients with measurable residual disease prior to transplant, with toxicities similar to busulfan and fludarabine

Source: healio.com
FDA rejects oleogel-S10 NDA for epidermolysis bullosa - Vimarsana News

FDA rejects oleogel-S10 NDA for epidermolysis bullosa

The FDA has denied a New Drug Application for oleogel-S10 for the treatment of the cutaneous manifestations of dystrophic and junctional epidermolysis bullosa, Amryt Pharma announced in a press release.In a complete response letter, the FDA requested additional efficacy evidence for oleogel-S10.

Source: healio.com